<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<rss version="2.0">
  <channel>
    <title>Chadha-Ajwani, S.</title>
    <link>http://repub.eur.nl/res/aut/6134/</link>
    <description>List of Publications</description>
    <language>en</language>
    <image>
      <url>http://repub.eur.nl/static-eur/img/logo.png</url>
      <title>RePub, Erasmus University Rotterdam</title>
      <link>http://repub.eur.nl</link>
    </image>
    <item>
      <title>Differences in invasive capacity of endometrial cancer cell lines expressing different progesterone receptor isotypes: possible involvement of cadherins (Article)</title>
      <link>http://repub.eur.nl/res/pub/15102/</link>
      <pubDate>2005-05-01T00:00:00Z</pubDate>
      <description>OBJECTIVE: Loss of expression of progesterone receptors (PR) in endometrial cancer is related to a more invasive and metastatic phenotype. In this study we aim to investigate whether selective loss of PRA or PRB affects the invasive capacity of endometrial cancer cells. METHODS: cDNA microarrays were performed to compare gene expression profiles of a set of endometrial cancer sub-cell lines expressing PRA and/or PRB. In vitro invasion assays were performed to assess whether differences in gene expression between the lines were reflected by their invasive behavior. RESULTS: It was observed that cell lines that express only PRA express higher levels of cadherins, and show a lower level of invasion compared to cell lines that express PRB. When cadherin function was inhibited in exclusively PRA-expressing cell lines, an increase of in vitro invasion was observed. In support of these findings, it was observed that in higher grade and more invasive endometrial cancer, expression of E-cadherin decreased. CONCLUSIONS: These results indicate that relative loss of PRA during progression of endometrial cancer can have a negative impact on cadherin expression, which may lead to development of a more metastatic phenotype.</description>
    </item> <item>
      <title>Consequences of loss of progesterone receptor expression in development of invasive endometrial cancer (Article)</title>
      <link>http://repub.eur.nl/res/pub/10230/</link>
      <pubDate>2003-01-01T00:00:00Z</pubDate>
      <description>PURPOSE: In endometrial cancer, loss of progesterone receptors (PR) is
      associated with more advanced disease. This study aimed to investigate the
      mechanism of action of progesterone and the loss of its receptors (PRA and
      PRB) in development of endometrial cancer. EXPERIMENTAL DESIGN: A
      9600-cDNA microarray analysis was performed to study regulation of gene
      expression in the human endometrial cancer subcell line Ishikawa PRAB-36
      by the progestagen medroxy progesterone acetate (MPA). Five MPA-regulated
      genes were selected for additional investigation. Expression of these
      genes was studied by Northern blot and by immunohistochemistry in Ishikawa
      subcell lines expressing different PR isoforms. Additionally, endometrial
      cancer tissue samples were immunohistochemically stained to study the in
      vivo protein expression of the selected genes. RESULTS: In the PRAB-36
      cell line, MPA was found to regulate the expression of a number of
      invasion- and metastasis-related genes. On additional investigation of
      five of these genes (CD44, CSPG/Versican, Tenascin-C, Fibronectin-1, and
      Integrin-beta 1), it was observed that expression and progesterone
      regulation of expression of these genes varied in subcell lines expressing
      different PR isoforms. Furthermore, in advanced endometrial cancer, it was
      shown that loss of expression of both PR and E-cadherin was associated
      with increased expression CD44 and CSPG/Versican. CONCLUSION: The present
      study shows that progestagens exert a modulatory effect on the expression
      of genes involved in tumor cell invasion. As a consequence, loss of PR
      expression in human endometrial cancer may lead to development of a more
      invasive phenotype of the respective tumor.</description>
    </item> <item>
      <title>Cytomegalovirus colitis in a CMV-seropositive renal transplant recipient on triple drug therapy (including mycophenolate) (Article)</title>
      <link>http://repub.eur.nl/res/pub/8743/</link>
      <pubDate>1997-01-01T00:00:00Z</pubDate>
      <description></description>
    </item>
  </channel>
</rss>